METRONIDAZOLE by Abbott is clinical pharmacology absorption disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. Approved for the treatment of asymptomatic t, the treatment of acute intestinal amebiasis (amebic dysentery), amebic liver abscess and 1 more indications. First approved in 1983.
Drug data last refreshed 7h ago · AI intelligence enriched 2d ago
Metronidazole is a small-molecule nitroimidazole antibiotic with bactericidal activity against anaerobic bacteria and protozoa. It is indicated for treatment of asymptomatic trichomoniasis, acute intestinal amebiasis, amebic liver abscess, and serious infections caused by susceptible anaerobic bacteria. The drug works by disrupting microbial DNA through intracellular reduction of its nitro group.
Product is nearing loss of exclusivity with significant generic competition; team focus shifts from growth to market defense and cost management.
CLINICAL PHARMACOLOGY Absorption Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma…
Worked on METRONIDAZOLE at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Working on metronidazole offers limited career growth given LOE approaching status and commodity market dynamics. Roles focus on cost management, market share defense, and operational excellence rather than innovation or brand building.